Of the six studies, four [7, 9, 13, 29, 38] found that KIT mutations did not significantly impact the prognosis of relapse risk, EFS, DFS, or OS, which was consistent with the findings in the largest study reported by Pollard et al. [7], which involved 203 pediatric patients with CBF-AML. This evidence concerns the gene KIT and acute myeloid leukemia.